samedan logo
 
 
 
spacer
home > ebr > summer 2008 > protein potential
PUBLICATIONS
European Biopharmaceutical Review

Protein Potential

Interferon alpha (IFNα) was one of the first FDA-approved biotherapeutic treatments. Since its approval, it has proved to be a powerful cytokine with potent therapeutic activity but, unfortunately, strong side effects. The overall use of IFNα increased dramatically when it was approved as the treatment of choice for hepatitis C.

However, nearly half of the individuals infected with genotype 1 of the virus still fail to respond to therapy (1). Consequently, several pharmaceutical companies are now trying to turn on the body’s own interferon alpha family of proteins using immunomodulatory molecules in the hope that this will elicit a more complete antiviral response. Both therapeutic approaches are not without risk, due to the side effects associated with IFNα. Additionally, there is a growing amount of published scientific articles suggesting that IFNα may be involved in certain autoimmune diseases, including systemic lupus erythematosus (SLE) (2).

Combined, these observations clearly suggest an increased need to monitor IFNα levels in both normal and diseased individuals along with patients undergoing therapy. How much IFNα produced by the body in response to new immunomodulatory therapies will be functionally equivalent to the current IFNα exogenous treatment regimen? How much ‘basal’ IFNα is beneficial to prevent or limit viral infection and how much is too much, thereby predisposing an individual to autoimmune disorders?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ronald G Jubin PhD is the current Research and Development Director at PBL InterferonSource. Previously, he was a Research Scientist with Schering-Plough from 1992 to 2004 in the antiviral therapy department, working on hepatitis C virus and interferon antiviral mechanisms. Whilst there, he published several papers that helped better define the mechanism of HCV translation. Ronald received his BA in Microbiology from Kean University, his MS degree in Microbiology from Seton Hall University and his PhD in Microbiology and Molecular Genetics from the University of Medicine and Dentistry of New Jersey, US.
spacer
Ronald G Jubin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Team Consulting expands facilities to meet client demand

To meet growing client demand, Team Consulting, a medical device design and development consultancy based in Ickleton, Cambridge, has expanded its facilities to now offer over 5,500 sq ft of lab spaces. Based in the picturesque 13th century Abbey Barns site, the company’s expansion sees the addition of a whole new building with several high-spec lab spaces, design facilities and collaborative workspaces.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement